NASDAQ:IMMU - Immunomedics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.01 -0.30 (-2.25 %)
(As of 01/22/2019 02:41 PM ET)
Previous Close$13.31
Today's Range$12.32 - $13.11
52-Week Range$11.55 - $27.33
Volume6.23 million shs
Average Volume4.06 million shs
Market Capitalization$2.48 billion
P/E Ratio-12.63
Dividend YieldN/A
Beta2.13
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 million
Book Value$2.39 per share

Profitability

Net Income$-273,830,000.00
Net Margins-12,701.21%

Miscellaneous

Employees185
Market Cap$2.48 billion
OptionableOptionable

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.06. Immunomedics had a negative return on equity of 85.57% and a negative net margin of 12,701.21%. During the same period in the previous year, the business posted ($0.97) EPS. View Immunomedics' Earnings History.

When is Immunomedics' next earnings date?

Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Immunomedics.

What price target have analysts set for IMMU?

8 brokerages have issued 1-year price objectives for Immunomedics' stock. Their predictions range from $17.00 to $55.00. On average, they expect Immunomedics' stock price to reach $28.75 in the next year. This suggests a possible upside of 120.7% from the stock's current price. View Analyst Price Targets for Immunomedics.

What is the consensus analysts' recommendation for Immunomedics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.

Has Immunomedics been receiving favorable news coverage?

News headlines about IMMU stock have trended very positive on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Immunomedics earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in December. As of December 31st, there was short interest totalling 28,429,341 shares, an increase of 9.1% from the December 14th total of 26,067,596 shares. Based on an average daily volume of 3,809,919 shares, the short-interest ratio is presently 7.5 days. Currently, 16.7% of the company's stock are sold short. View Immunomedics' Current Options Chain.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:
  • Mr. Michael F. Pehl, Pres, CEO & Director (Age 54)
  • Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
  • Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
  • Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)
  • Mr. Michael R. Garone, VP of Fin. (Age 60)

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.01%), Union Bankshares Corp (0.01%) and North Star Investment Management Corp. (0.00%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Which major investors are buying Immunomedics stock?

IMMU stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Union Bankshares Corp and North Star Investment Management Corp.. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $13.0250.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $2.48 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 185 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is http://www.immunomedics.com.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  305 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  575
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel